Biosimilars core EBITDA margins to return to mid-thirties by end of FY24
Management expects core EBITDA margins for Biocon Biologics to recover to mid-thirties as legacy rebate issues normalize and integration completes.
BIOCON / guidance tracker
Keep management guidance in view.
Biocon · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
Generics mid-teen revenue growth for FY24
Generics segment guided for mid-teen revenue growth for the fiscal year, with better second half due to capacity expansions and new product launches.
Generics high double-digit CAGR over 5 years
Generics business expected to grow at 17-20% CAGR over the next 4-5 years, driven by peptides, injectables, and fermentation.
Biocon Biologics CapEx of $150 million for FY24
Capital expenditure for biosimilars business guided at $150 million, primarily for Malaysia expansion and insulin capacity ramp-up.
H2 FY25 growth acceleration
Management expects Q2 to be similar to Q1, with a transition to accelerated growth in the second half of FY25, driven by biosimilars traction, new generic launches, and Syngene momentum.
Generics high single-digit growth for FY25
Generics business is expected to deliver high single-digit revenue growth for the full year, with H2 significantly stronger than H1.
Ustekinumab launch in Q4 FY25
Biocon expects to launch ustekinumab (Stelara biosimilar) in the US in the last quarter of FY25, subject to FDA approval and settlement agreements.
Debt reduction priority
Management intends to reduce debt further during FY25, following a $250 million reduction last year, but no specific timeline or amount was provided.
Generics double-digit revenue growth for FY26
Management expects strong double-digit revenue growth for the generics segment for the full fiscal year, driven by multiple product launches including liraglutide in Europe and the U.S.
Liraglutide U.S. approval expected this fiscal
Liraglutide U.S. file is under FDA review with a target action date; approval and launch expected during FY26.
Denosumab U.S. approval by end of calendar 2025
Biocon Biologics expects U.S. FDA approval for denosumab before the end of calendar 2025.
Semaglutide filings in Q2 FY26 for emerging markets and Canada
Semaglutide will be filed in Q2 FY26 in many emerging markets and Canada, with best-case approval by end of calendar 2026.
Biocon Biologics to deliver $1 billion revenue in FY24
Management reaffirmed full-year revenue guidance of $1 billion for Biocon Biologics, driven by market share gains and new product launches.
Syngene mid-teen constant currency growth for FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
Generics H2 performance to improve over H1
Generics business expects improved second half performance, with formulations steady at ~INR 400 crore per half and API recovery, but full-year growth revised to low teens/high single digit.
Ustekinumab filing on track by end of 2023
Biocon Biologics remains on track to file ustekinumab (Stelara biosimilar) before the end of 2023, with denosumab filing expected by end of next year.
H2 FY25 acceleration in growth
Management expects a transition to accelerated growth in H2, driven by Syngene returning to growth, maintained biosimilars momentum, and generics recovery from new launches.
Liraglutide launch in UK in Q3 FY25
First generic Liraglutide approved in UK; launch expected in Q3 FY25, contributing to generics recovery.
Ustekinumab launch in US in Q4 FY25
Biocon Biologics expects to launch biosimilar Ustekinumab in the US in Q4 FY25, pending FDA approval.
Generics mid-teens growth over next couple of years
Generics business targets mid-teens revenue growth over the next two years, driven by peptides, new OSDs, and injectables.
Biosimilar R&D spend at 7-9% of revenue
Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.
Generics R&D spend at 8-10% of revenue
Generics R&D spend is expected to be in the 8-10% range of segment revenue.
Generics gross margin improvement in H2
Gross margins in generics are expected to improve in the second half of FY26, driven by new product launches.
Syngene maintains FY26 annual guidance
Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.
BBL core EBITDA margin target of mid-30s
Management reiterated a mid-30s core EBITDA margin target for Biocon Biologics, with current margins depressed by ~5% due to integration-related one-off costs expected to normalize.
Generics business targeting mid-teens growth next fiscal
Generics business aims to return to mid-teens growth in FY25, driven by formulations momentum and new peptide revenues, despite current API pricing pressure.
Debt reduction focus with $200M repaid in Q3
Management emphasized continued debt reduction, having repaid $200M of acquisition debt in Q3, with further deleveraging expected from cash flows and other options.
Syngene facility operational in H2 FY25
The acquired Stelis biologics facility is expected to be operational in the second half of FY25, subject to regulatory approvals, adding 20,000L capacity.
Biosimilar Ustekinumab launch in February 2025
Yesintek (biosimilar to Stelara) will launch in the US in February 2025, with a global rollout including Europe.
Generic liraglutide launch in UK in Q4 FY25 and EU in Q1 FY26
First GLP-1 generic will launch in the UK in Q4 FY25, followed by EU national launches in Q1 FY26.
Generics mid-teens growth in FY26
Generics business expected to return to mid-teens growth in FY26, driven by liraglutide and other launches.
Biosimilar Bevacizumab and Aspart US approvals pending site clearance
With VAI status for manufacturing sites, management expects expedited FDA review for these biosimilars.
Annualized interest savings of ~₹300 crore from FY27
Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt.
Biosimilar EBITDA margin to be in mid-20s for full year FY26
Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%.
Capex to moderate to <$225 million and further decline
Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes.
Insulin drug product capacity to double in FY27
The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.
Syngene FY25 revenue growth: single-digit to low double-digit
Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.
Syngene FY25 EBITDA margin similar to FY24
Syngene expects operating EBITDA margin to be similar to FY24 levels (~31%).
Biosimilars R&D spend 8%-9% of revenues
Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.
Generics growth back-ended in FY25
Generics performance expected to build throughout the year with stronger second half, driven by new formulation launches.
Five biosimilar launches in 12-18 months
Management expects to launch Yesintek (launched), Bevacizumab, Aspart, Aflibercept (US H2 2026), and Denosumab within the next 12-18 months.
Capital raise of INR 4,500 crore via QIP/private placement
First tranche expected to complete by mid-June 2025; proceeds primarily to meet structured debt obligations from Biocon Biologics investments.
CapEx of ~$150 million over next two years
Biologics CapEx of ~$100 million (Malaysia expansion) and generics CapEx of ~$50 million; thereafter largely maintenance CapEx from FY27.
Liraglutide US approval expected in H2 CY2025
Target action date in H2 2025; facility cleared, queries responded; ready to launch immediately upon approval.
Biosimilar revenue growth of 16% in FY26 on like-to-like basis
Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.
EBITDA margin expansion of ~200bps in FY26 on like-to-like basis
Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up.
Net debt reduction to ~$1.1B from $1.5B in March 2025
Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected.
Aflibercept (Yesafili) launch in US in H2 FY27
Settlement with originator allows entry; management expects meaningful revenue contribution from H2.